PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

·	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are	required to respond to a collection of information unless it contains a valid OMB control number.
	Complete if Known Co. 1 C. C.

Substitute for form 1449/PTO			Complete if Known A Q R		
				Application Number	Not Yet Known
INFORMATION DISCLOSURE				Filing Date	Herewith
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Gabriella MINCHIOTTI
(Use as many sheets as necessary)				Art Unit	Not Yet Known
(036 as many sheets as necessary)			ecessary)	Examiner Name	Not Yet Known
Sheet	1	of	2	Attorney Docket Number	1118-PCT-US

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	PCT International Search Report for Minchiotti, et al., Int'l Application No. PCT/IT04/000133, Filed March 19, 2004, Dated September 2, 2004	
	2	PICCOLO, et al., "The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals", Nature, Vol. 397, No. 6721, Pages 707-710 (1999)	
	3	PARISI, et al., "Nodal-dependent Cnpto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells", Journal of Cell Biology, Vol. 163, No. 2, Pages 303-314 (2003)	
	4	ADAMSON, et al., "Cripto: A tumor growth factor and more", Journal of Cellular Physiology, Vol. 190, No. 3, Pages 267-278 (2002)	
	5	XU, et al., "Specific arrest of cardioegensis in cultured embryonic stem cells lacking Cripto-1", Developmental Biology, Vol. 196, No. 2, Pages 237-247 (1998)	
	6	BALDASSARRE, et al, "Transfection with a Cripto anti-sense plasmid suppresses endogenous Cripto expression and inhibits transformation in a human embryonal carcinoma cell line", International Journal of Cancer, Vol. 66, No. 4, Pages 538-543 (1996)	

Examiner	/Daniel Gamett/ (12/11/2008)	Date	
Signature	, , , , , , , , , , , , , , , , , , , ,	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) end select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

JC20 Rec'd PCT/PTO 2 0 SEP 200

PTO/SB/08A (02-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449/PTO

Complete if Known NőtlYét kindvyő Application Number Filing Date Herewith First Named Inventor Gabriella MINCHIOTTI Art Unit Not Yet Known **Examiner Name** Not Yet Known

Attorney Docket Number 1118-PCT-US Sheet 2

	1 0'4		U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
		US-	<del>                                     </del>		
		US-			
		US-		*******	
		US-			
····		US-			
		US-		···	
		US-			

Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Τ
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T'
	7	WO 01/68814 A2	09-20-2001	Advanced Research & Technology Institute, Inc.		
	8	WO 2004/053084 A2	06-24-2004	The Mclean Hospital Corporation		
	9	WO 02/26941 A2	04-04-2002	Van Der Kopy, Derek		
		·				

Examiner Signature	/Daniel Gamett/ (12/11/2008)	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.